Reversal of resistance towards cisplatin by curcumin in cervical cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1403-1410

  Roy, Madhumita ^a   Mukherjee, Sutapa ^b  

^a Department of Environmental Carcinogenesis and Toxicology ^*  (India)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Cervical cancer; Cisplatin; E6 E7; HDACs; MDR

Indexed keywords

ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CISPLATIN; CURCUMIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ENZYME INHIBITOR; GLUTATHIONE; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HERMES ANTIGEN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN;

ACETYLATION; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

ACETYLATION; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; CURCUMIN; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GLUTATHIONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; S PHASE CELL CYCLE CHECKPOINTS; UTERINE CERVICAL NEOPLASMS;

EID: 84896838073     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1403     Document Type: Article

References (42)

1. Basu P, Dutta S, Begum R, et al (2013). Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: A phase II randomized controlled study. Asian Pac J Cancer Prev, 14, 5753-59.
2. Biswas J, Roy S, Mukherjee S, et al (2010). Indian spice curcumin may be an effective strategy to combat the genotoxicity of arsenic in swiss albino mice. Asian Pac J Cancer Prev, 11, 239-46.
3. Brehm A, Nielsen SJ, Miska EA, et al (1999). The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. Embo J, 18, 2449-58.
4. Cheah PL, Looi LM, Teoh KH, et al (2012). p16(INK4a) is a useful marker of human papillomavirus integration allowing risk stratification for cervical malignancies. Asian Pac J Cancer Prev, 13, 469-72.
5. Chekhun VF, Lukyanova NY, Kovalchuk O, et al (2007). Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper-and hypomethylated targets. Mol Cancer Ther, 6, 1089-98.
6. Choi BH, Kim CG, Lim Y, et al (2008). Curcumin downregulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFκB pathway. Cancer Lett, 259, 111-18.
7. Dai X-Z, Yin H-T, Sun L-F, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-59.
8. Dong X, Mumper RJ (2010). Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine, 5, 597-615.
9. Ermakova SP, Kang BS, Choi BY, et al (2006). (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res, 66, 9260-69.
10. Huang BH, Laban M, Leung CH, et al (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase1. Cell Death Differ, 12, 395-404.
11. Jayshree RS, Sreenivas A, Tessy M et al (2009). Cell intrinsic and extrinsic factors in cervical carcinogenesis. Indian J Med Res, 130, 286-95.
12. Kim H, Kim SN, Park YS, et al (2011). HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int J Oncol, 38, 807-12.
13. Kuo MT (2009). Redox regulation of multidrug resistance in cancer chemotherapy: Molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal, 11, 99-133.
14. Lin Z, Bazzaro M, Wang M-C, et al (2009). Combination of proteasome and HDAC inhibitors for therapy of uterine cervical cancer. Clin Cancer Res, 15, 570-77.
15. Longworth MS, Laimins LA (2004). The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papilloma virus type 31. J Virol, 78, 3533-41.
16. Luczak MW, Jagodzinski PP (2008). Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells. Cancer Lett, 272, 53-60.
17. Maher DM, Bell MC, O'Donnell EA, et al (2011). Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo(a)pyreneinduced upregulation of HPV-E7. Mol Carcinog, 50, 47-57.
18. Mahjoubi F, Akbari S (2013). Multidrug resistance-associated protein 1 predicts relapse in Iranian childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev, 13, 2285-9.
19. Malumbres M, Barbacid M (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer, 9, 153-66.
20. Mizuguchi Y, Specht S, Lunz JG III, et al (2012). SPRR2a enhances p53 deacetylation through HDAC1 and downregulates p21 promoter activity. BMC Mol Cancer, 13, 20-9.
21. Möckel J, Quaas J, Meisel H, Endres AS, Schneider V (2011). Human papillomavirus E6/E7 mRNA testing has higher specificity than liquid-based DNA testing in the evaluation of cervical intraepithelial neoplasia. Anal Quant Cytol Histol, 33, 311-5.
22. Mukherjee S, Sarkar R, Biswas J, Roy M (2012) Curcumin inhibits histone deacetylase leading to cell cycle arrest and apoptosis via up-regulation of p21 in breast cancer cells. Int J Green Nanotech, 4, 183-97.
23. Munger K, Basile JR, Duensing S, et al (2001). Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene, 20, 7888-98.
24. Narisawa-Saito M, Kiyono T (2007). Basic mechanisms of highrisk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci, 98, 1505-11.
25. Raybould R, Fiander A, Hibbitts S (2011). Human papillomavirus integration and its role in cervical malignant progression. The Open Clinical Cancer J, 5, 1-17.
26. Roy M, Mukherjee S, Sarkar R, Biswas J (2011). Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NFκB and HDAC in breast cancer. Ther Delivery, 2, 1275-93.
27. Sahin K, Tuzcu M, Basak N, et al (2012). Sensitization of cervical cancer cells to cisplatin by genistein: The role of NFκB and Akt/mTOR signaling pathways. J Oncol, 2012, 1-6.
28. Sarkar FH, Li Y (2006). Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res, 66, 3347-50.
29. Singh M, Singh N (2011). Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol Cell Biochem, 347, 1-11.
30. Singh M, Singh U, Mathur N, et al (2012). Expression of p-glycoprotein is positively correlated with p53 in human papilloma virus induced squamous intraepithelial lesions of uterine cervix: poor prognosis association. Asian Pac J Cancer Prev, 13, 6039-45.
31. Song W, Jiang R, Zhao C-M (2012). Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cell. Asian Pac J Cancer Prev, 13, 5619-25.
32. Subramanian N, Chinnappan S (2013). Prediction of promiscuous epitopes in the E6 protein of three high risk human papilloma viruses: a computational approach. Asian Pac J Cancer Prev, 14, 4167-75.
33. Szakacs G, Paterson JK, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219-34.
34. Takai N, Kira N, Ishii T, et al (2011). Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev, 12, 575-80.
35. Tanaki T, Fukasawa K, Suzuki-Takahashi I, et al (2004). Cdkmediated phosphorylation of pRB regulates HDAC binding in vitro. Biochem Biophys Res Commun, 316, 252-5.
36. Tyagi AK, Agarwal C, Chan DC, et al (2004). Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Reports, 11, 493-9.
37. Vinod BS, Maliekal TT, Anto RJ (2013). Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxidants and Redox Signaling, 18, 1307-48.
38. Wesierska-Gadek J, Krystof V (2009). Selective cyclindependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia? Ann NY Acad Sci, 1171, 228-41.
39. Witt O, Deubzer HE, Milde T, et al (2009). HDAC family: What are the cancer relevant targets? Cancer Lett, 277, 8-21.
40. Yin HT, Zhang DG, Wu XL, et al (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12.
41. Zhang E-Y, Tang X-D (2012). Human papillomavirus type 16/18 oncoproteins: potential therapeutic targets in non-smoking associated lung cancer. Asian Pac J Cancer Prev, 13, 5363-9.
42. Zhou X, Gu Y, Zhang S-L (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: A huge review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14.